# Organon & Co. Common Stock (OGN) fundamentals

Data as of 2026-09-08. NYSE, United States. Sector: Healthcare / Biotechnology. Price $13.78, market value $3.6 billion.

## Valuation
- **P/E (trailing): 17.7×** (5-yr avg 5.8×, 3-yr avg 5.9×). Organon & Co. Common Stock trades at 17.7× trailing earnings, well above its own five-year average of 5.8×: investors are paying up relative to the company's past. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 3.8×, lower than trailing, so analysts expect earnings to grow.
- **Price / sales: 0.6×**. Each dollar of revenue is priced at 0.6×, a low multiple typical of thin-margin businesses or out-of-favour stocks.
- **Price / book: 3.6×**. The shares trade at 3.6× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: 15.7%** (5-yr avg 21.4%). Free cash flow equals 15.7% of the market value, below its five-year average of 21.4%, so the shares are pricier on cash than usual. Above 5% is generally attractive.
- **Earnings yield: 5.7%**. The inverse of the P/E: 5.7% of the price is earned each year.

## Profitability
- **Gross margin: 52.7%**. Organon & Co. Common Stock keeps 52.7% of revenue after the direct cost of what it sells.
- **Net margin: 3.0%**. 3.0% of each dollar of sales reaches the bottom line.
- **Return on equity: 24.9%**. 24.9% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.
- **Return on assets: 1.6%**. Each dollar of assets produces 1.6% of profit.

## Growth
- **Revenue growth (1 yr): -2.9%** (3-yr 0.2%/yr, 5-yr -1.0%/yr). Revenue fell 2.9% over the last year, against -1.0% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): -78.4%** (3-yr -41.5%/yr, 5-yr -39.0%/yr). Earnings per share fell 78.4%, slower than revenue, so margins compressed.
- **Free-cash-flow growth (3 yr): -6.7%/yr**. Free cash flow has compounded at -6.7% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 11.49**. Debt is 11.49 times equity, a leveraged balance sheet that needs steady cash flow to service.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend yield: 0.58%** ($0.08 per share, trailing). Organon & Co. Common Stock yields 0.58%, a modest yield more typical of a growth-oriented payer.
- **Payout ratio: 47%** (3% of free cash flow). 47% of earnings goes out as dividends, leaving room to keep raising it.

## Analyst view
- **Analyst consensus: hold** (4 analysts). 4 analysts cover Organon & Co. Common Stock; the consensus is hold, with an average price target of $11.25 (-18% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 43.3%** (YTD 93.0%, 3-mo 3.1%). The shares are up 43.3% over twelve months including dividends.
- **From 52-week high: -0.0%** (142.2% above the low). Trading within 5% of its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 76**. An RSI of 76 is in overbought territory; short-term pullbacks are common from here.
- **Beta (1 yr): 0.73** (volatility 66%). Beta of 0.73 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=OGN · Page: https://foliofundamentals.com/stocks/ogn

Not investment advice.